Demonstrating extremely high accuracy for negatively diagnosing bladder cancer, the test also correctly identified bladder cancer-associated genes in 71 of 77 patients who went on to develop a malignancy. While the study authors acknowledged several limitations associated with observational clinical trials, they emphasized that cystoscopy—the current standard test method—is expensive and time-consuming when compared to the remarkable ease with which a patient can provide a simple urine sample.
Bladder cancer remains one of the ten most common malignancies worldwide, with approximately 550,000 new cases diagnosed globally every year. In the United States, it ranks as the sixth most common cancer, and the Centers for Disease Control and Prevention (CDC) estimates that roughly 84,000 individuals will receive a diagnosis this year alone. Early and accurate detection is critical for improving patient outcomes, yet the traditional diagnostic workflow presents significant hurdles for both patients and healthcare infrastructure.
A key symptom in diagnosing bladder cancer is hematuria, the medical term for blood in the urine. Although hematuria is present in more than 90% of patients ultimately diagnosed with bladder cancer, only 8% to 19% of all hematuria referrals ever result in a positive cancer test. This enormous shortfall between symptom presentation and confirmed diagnosis occurs in part due to the complexity, cost, and invasive nature of current gold-standard testing methods.
Flexible cystoscopy, urinary tract imaging, and the analysis of resected tissue, when combined, are considered the highest-quality diagnostic procedure. However, these methods are expensive, invasive, and require in-person medical appointments. They demand significant resources, scheduling availability, and specialized clinical staff, creating bottlenecks for urology departments and increasing patient anxiety.
To address these challenges, developers have turned to molecular profiling. The test evaluated in the UK study, known as GALEAS Bladder, was developed by Nonacus Clinical Services. It subjects a simple urine sample to a sophisticated multimarker genetic assay, analyzing proteins and other traces of 23 distinct genes associated with the development of bladder cancer.
Beyond being quick and inexpensive, a major advantage of the GALEAS platform is its versatility. It can be run using urine samples collected for other routine clinical reasons, raising the possibility of identifying early signs of bladder cancer in individuals who might not have been previously considered at risk.
Andy Goffe, a Lead Urology Nurse Consultant at Dorset County Hospital Foundation Trust in the UK, who leads the GALEAS Bladder service evaluation, emphasized the patient-centric nature of the testing approach. "The most important message for the patient is that they don’t have to do anything to be part of this," Goffe stated.
"We also explain that we’re looking for ways to replace a cystoscopy, so perhaps it is not a surprise that, to date, 100% of patients have agreed to get involved," he added.
In the recent study, published in European Urology Oncology, researchers examined and recorded the urine samples of 964 patients referred for urgent hematuria screening as part of a suspected cancer pathway between 2024 and 2025. All participants in the cohort underwent standard diagnostic procedures alongside the investigational GALEAS test to allow for a direct comparison of efficacy.
Out of the 77 total cases of bladder cancer identified through standard cystoscopy, the GALEAS test successfully detected 71. This included all 17 muscle-invasive cancers and 35 out of the 36 later-stage cancers present in the study group. Furthermore, the negative predictive value—representing the test’s accuracy when ruling out the disease—was greater than 99%, highlighting its strength as a reliable indicator of health for patients who do not have the condition.
The evaluation also documented the test’s limitations. It produced 61 false-positive results, and among the six false-negative outcomes, four cases occurred when the cancer tumor was at an exceptionally early stage of development. Despite these false positives, the study’s authors concluded that as a triage device, the test demonstrated considerable reliability, efficacy, and accuracy.
Researchers and clinical staff involved in the evaluation believe that widespread adoption of such non-invasive tools could reshape clinical workflows. "Ultimately, this could lead to a considerable reduction in the number of urgent cystoscopies undertaken in this setting, thereby reducing waiting times," the authors noted. By filtering out low-risk patients who present with hematuria due to benign causes, hospitals could prioritize invasive cystoscopies for individuals who require immediate intervention, easing the burden on overburdened healthcare systems and improving the overall patient journey.
